Amos Hedt

Amos Hedt

Company: Viewpoint Molecular Targeting, Inc

Job title: Chief Business Strategy Officer


Pb-203/Pb-212: an Emerging Theranostic Isotopologue 12:00 pm

Theranostic pairs: what implications are there for matched and non-matched elements? Chemical, biological, developmental, logistical, commercial and regulatory aspects Pb-203/Pb-212 history, current state of development, and future potential. Next steps for radiopharmaceuticals: the curative potential of combination therapies. Targeted alpha particle therapy is showing great promise in combination with immunotherapy.Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.